Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

Kathleen N. Moore, Toon Van Gorp, Tashanna Myers et al.|Journal of Clinical Oncology|2023

Cited by 53